Skin & hair

Why Transplant Patients Face a Much Higher Skin-Cancer Risk

Save

Transplant recipients develop skin cancer far more often than the general population, a direct consequence of long-term immunosuppression. This guide explains why the risk climbs, which skin cancers matter most and how they behave, what sun protection actually changes, and how a dermatology skin-check routine fits into life after a transplant.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Why transplant recipients get so much more skin cancer

After a transplant, you take immunosuppressant medicines for life so your body does not reject the new organ. Those same medicines dial down the immune surveillance that normally spots and clears sun-damaged and abnormal skin cells before they become cancer. Meanwhile, ultraviolet damage keeps accumulating. The result is that skin-cancer risk climbs well above that of the general population, and it stays elevated for as long as immunosuppression continues.

Two forces combine. Ultraviolet radiation from the sun and tanning beds is the main modifiable cause of skin cancer, damaging the DNA in skin cells over years 1. In a healthy immune system, many of those damaged cells are caught and removed. Under immunosuppression, more of them survive and progress, which is why immunosuppression is treated as a recognized high-risk feature in how squamous cell carcinoma is stratified and managed 2.

Transplant medicines do not cause cancer directly; they remove a layer of defense while sun damage keeps building. That is the core of the connection between immunosuppression and skin cancer.

Squamous cell carcinoma leads the list

Squamous cell carcinoma is the skin cancer that increases the most after a transplant, and it can behave more aggressively than it does in people who are not immunosuppressed. It tends to appear on sun-exposed areas: the face, ears, scalp, lips, backs of the hands, and forearms. Because immunosuppression marks these tumors as higher risk, they are watched and treated more assertively.

In skin-cancer risk stratification, immunosuppression is one of the features that pushes a squamous cell carcinoma into the high-risk category, which changes how it is managed. High-risk tumors are treated more assertively, and Mohs micrographic surgery is often used to clear them while checking the margins during surgery 2.

Because the risk stays elevated for as long as immunosuppression continues, new or changing spots are worth checking as they appear. It is also why transplant recipients often ask about recurrent skin cancer risk and second primary skin cancer risk after a first diagnosis.

Basal cell carcinoma and melanoma still matter

Squamous cell carcinoma gets the most attention after a transplant, but it is not the only concern. Basal cell carcinoma still occurs and is usually slow-growing and local, though it too needs treatment to stop it enlarging and invading nearby tissue. Melanoma, the less common but more dangerous skin cancer, also warrants attention, which is why any changing mole deserves evaluation.

Basal cell carcinoma is diagnosed by biopsy and typically treated with surgical removal, with Mohs surgery reserved for higher-risk or facial tumors 3. Because so many of these cancers appear on the head and neck, it helps to know the pattern of skin cancer on the face and to recognize skin cancer on ear signs, since the ears and other sun-exposed edges are easy to overlook.

Melanoma is far less common than the keratinocyte cancers, but its outcome depends heavily on how early it is found. Nationally, most melanomas are caught while still localized. Localized melanoma has about a 100% five-year relative survival, versus about 34% once it has spread to distant sites 4. That gap is the whole argument for finding changes early.

What to watch for, and when to act

The practical task is to notice change and act on it. On immunosuppressed skin, a lesion that is new, growing, scaly, crusted, bleeding, or simply not healing deserves attention, and because these cancers can behave aggressively, it is better to have a changing spot looked at within weeks than to watch it for months 2. Photograph anything questionable with a ruler for scale and note the date.

Red flags on transplant skin include a firm or tender nodule that is enlarging, a sore that will not heal, a rough or scaly patch that keeps growing back, and any mole that is changing in size, shape, or color. None of these confirms cancer, and none can be ruled out from a photo, but each is a reason to be seen rather than reassured from a distance.

Keep a simple record. Comparing dated photos makes real change obvious and gives a dermatologist something concrete to work from at your next skin check.

Protecting your skin after a transplant

Sun protection does more for transplant recipients than for almost anyone, because it addresses the one major risk factor still in your control. Reducing ultraviolet exposure lowers the ongoing DNA damage that immunosuppression can no longer keep in check. Daily broad-spectrum sunscreen, protective clothing, hats, shade, and avoiding tanning beds are the practical core of that effort.

The evidence for daily sunscreen is real: in a long-term randomized trial, adults who applied sunscreen regularly developed fewer melanomas over the following years than those who used it only occasionally 5. Broad-spectrum protection matters because both UVA and UVB contribute to skin damage.

Ultraviolet light from the sun and tanning beds remains the main modifiable driver of skin cancer, so cutting that dose is the highest-yield habit after a transplant 1. Sun protection does not undo existing damage, but it slows the accumulation of new damage on skin that has lost part of its natural defense.

How often to be checked, and what screening evidence says

Transplant recipients generally need closer dermatologic follow-up than the average person, with the exact schedule set by your transplant team and dermatologist based on your history and how many skin cancers you have had. This is different from population screening: it is targeted surveillance of a known high-risk group, arranged individually rather than by a one-size rule.

It is worth understanding the screening evidence so it is not misread. The US Preventive Services Task Force found insufficient evidence to weigh the benefits and harms of routine whole-body skin-cancer screening in adults who have no symptoms 6. That statement is about the general, average-risk population; it does not speak to the individualized surveillance that clinicians provide to transplant recipients and others at high risk.

If you want the specifics of a monitoring routine, our companion guidance on how often skin check on immunosuppressants and immunosuppressed skin cancer surveillance goes deeper, and the general advice on who should get regular skin checks is a useful starting point. If cost is a barrier between visits, free skin cancer screening events, including AAD SPOTme screening, are one way to get an interim look.

Common questions

Substantially higher than in the general population, and the increase is greatest for squamous cell carcinoma. The exact size depends on how long and how intensely you are immunosuppressed, your skin type, your prior sun exposure, and how many skin cancers you have already had. Rather than fixating on a number, the useful takeaway is that the risk is high enough to justify lifelong sun protection and regular dermatology skin checks.

The risk is tied to immunosuppression as a whole rather than to a single drug, since the shared effect is a weakened ability to clear damaged skin cells. Some regimens carry more skin-cancer risk than others, and transplant teams sometimes adjust medicines with that in mind. Any changes to anti-rejection therapy are decisions for your transplant team, weighing organ protection against other risks.

Squamous cell carcinoma rises the most after a transplant, so it gets the most attention, but melanoma still matters because its outcome depends so heavily on early detection. Localized melanoma is highly survivable, while melanoma found after it has spread is far more dangerous. That is why any mole changing in size, shape, or color deserves evaluation, not just non-healing sores.

Sun protection cannot restore the immune surveillance that immunosuppression reduces, but it directly cuts the ultraviolet damage that drives skin cancer. In long-term research, regular sunscreen use was linked to fewer melanomas over time. Combined with clothing, hats, shade, and avoiding tanning beds, daily broad-spectrum sunscreen is one of the highest-value habits a transplant recipient can keep.

Not inevitably, but a first skin cancer after a transplant signals that your skin is producing cancers, and the underlying risk remains as long as immunosuppression continues. Many transplant recipients ask about recurrent skin cancer risk for exactly this reason. The practical response is steady follow-up so new lesions are found early, when treatment is simplest.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Skin changes to act on after a transplant

  • —A firm, scaly, or crusted spot that is growing or will not heal, especially on the face, ears, scalp, lips, or backs of the hands
  • —A sore that bleeds, scabs, and reopens in the same place over weeks
  • —A mole or dark spot that is changing in size, shape, or color, or a new pigmented spot
  • —A rapidly enlarging or tender lump on sun-exposed skin

This article is health information, not a diagnosis, and it does not replace your transplant team's guidance. No one can tell from a photo or a description whether a spot is cancer; only an in-person exam and, when needed, a biopsy can. Bring any changing or non-healing lesion to your dermatologist or transplant team.

References

  1. 1.National Cancer Institute (PDQ Screening and Prevention Editorial Board) (2025). Skin Cancer Prevention (PDQ®)–Health Professional Version. NIH / National Cancer Institute. link ✓Ultraviolet radiation from the sun and tanning beds is the main modifiable cause of skin cancer, damaging skin-cell DNA over years; reducing UV exposure lowers risk.
  2. 2.Kim JYS, Kozlow JH, Mittal B, et al. (2018). Guidelines of care for the management of cutaneous squamous cell carcinoma. Journal of the American Academy of Dermatology. doi:10.1016/j.jaad.2017.10.007Immunosuppression is a recognized high-risk feature in cutaneous squamous cell carcinoma risk stratification; high-risk tumors are managed more assertively, including with Mohs micrographic surgery.
  3. 3.Kim JYS, Kozlow JH, Mittal B, et al. (2018). Guidelines of care for the management of basal cell carcinoma. Journal of the American Academy of Dermatology. doi:10.1016/j.jaad.2017.10.006Basal cell carcinoma is diagnosed by biopsy and treated with surgical excision, with Mohs micrographic surgery reserved for higher-risk or facial tumors.
  4. 4.National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program (2025). Cancer Stat Facts: Melanoma of the Skin. NIH / National Cancer Institute (SEER). linkMost melanomas are diagnosed at a localized stage; localized melanoma has about a 100% five-year relative survival, versus about 34% for distant-stage disease.
  5. 5.Green AC, Williams GM, Logan V, Strutton GM (2011). Reduced Melanoma After Regular Sunscreen Use: Randomized Trial Follow-Up. Journal of Clinical Oncology. PMID 21135266 ✓In long-term randomized follow-up, adults who used sunscreen regularly developed fewer melanomas than those who used it only occasionally.
  6. 6.US Preventive Services Task Force (2023). Skin Cancer: Screening. US Preventive Services Task Force. link ✓The USPSTF found insufficient evidence to weigh the benefits and harms of routine whole-body skin-cancer screening in asymptomatic adults; this does not address individualized surveillance of high-risk groups such as transplant recipients.

6 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — citations link their sources. Editorial policy

← Back to the health library